Is ALNY a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Amvuttra ATTR-CM ramp, with net product revenue (fy2025) at ~$3.0B. The bear case rests on revenue is heavily concentrated in the TTR franchise, so any competitive share loss or reimbursement setback for Amvuttra would hit the whole story. Analysts covering it are spread from $285.00 to $551.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Revenue is heavily concentrated in the TTR franchise, so any competitive share loss or reimbursement setback for Amvuttra would hit the whole story. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $285.00, -1.3% from the $288.76 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Amvuttra ATTR-CM ramp. The March 2025 approval of Amvuttra for ATTR cardiomyopathy opened a market many multiples larger than its original polyneuropathy indication, and the launch is the single biggest growth driver. The most optimistic analyst target on ALNY is $551.00, +90.8% from the $288.76 price. That figure is only reachable if this thesis works close to its best case.

Revenue is heavily concentrated in the TTR franchise, so any competitive share loss or reimbursement setback for Amvuttra would hit the whole story. The ATTR-CM market is now a genuine contest, with Pfizer's entrenched tafamidis (Vyndaqel/Vyndamax), BridgeBio's oral acoramidis (Attruby), and Ionis/AstraZeneca's eplontersen (Wainua) all competing. Biotech valuations are sensitive to clinical trial outcomes, and pipeline readouts in Alzheimer's and other areas could disappoint. The stock trades at a rich multiple of revenue that assumes years of strong growth, leaving room for sharp drawdowns on any stumble. Drug pricing pressure and patent or regulatory changes are ongoing overhangs for the sector. The most pessimistic published target is $285.00, -1.3% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Alnylam Pharmaceuticals is the company that turned RNA interference, a Nobel-winning biological mechanism for silencing disease-causing genes, into an approved class of medicines.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Amvuttra ATTR-CM ramp) stalling in the reported numbers rather than in the narrative, the risk above (revenue is heavily concentrated in the TTR franchise, so any competitive share loss or reimbursement setback for Amvuttra would hit the whole story) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Alnylam develops and sells RNA interference (RNAi) therapeutics, medicines that silence disease-causing genes. Its main products treat TTR amyloidosis (Amvuttra and Onpattro), acute hepatic porphyria (Givlaari), and a rare kidney disorder (Oxlumo). It also earns royalties on Leqvio, an RNAi cholesterol drug sold by Novartis. The company pioneered turning the RNAi mechanism into a repeatable drug-development platform.

Amvuttra (vutrisiran) is Alnylam's largest revenue driver by a wide margin. Its March 2025 FDA approval for ATTR cardiomyopathy expanded it into a much bigger patient population than its original nerve-disease indication. That single approval is the main reason revenue nearly doubled and the company reached profitability. Because so much revenue rests on it, Amvuttra's performance largely defines the investment case.

Yes. After years of heavy research spending, Alnylam reached both GAAP and non-GAAP profitability for full-year 2025 on roughly $3 billion of net product revenue. In Q1 2026 it reported about $206 million of net income on roughly $1.0 billion of net product revenue. Management expects operating income to keep growing as the Amvuttra launch scales.